Diamine derivatives

Details Diamine derivatives Diamine derivatives

C - Chemistry, Metallurgy

07

D

C07D 401/12 (2006.01) A61K 31/428 (2006.01) A61K 31/429 (2006.01) A61K 31/4365 (2006.01) A61K 31/437 (2006.01) A61K 31/4439 (2006.01) A61K 31/444 (2006.01) A61K 31/454 (2006.01) A61K 31/4545 (2006.01) A61K 31/4709 (2006.01) A61K 31/4725 (2006.01) A61K 31/496 (2006.01) A61K 31/501 (2006.01) A61K 31/502 (2006.01) A61K 31/5025 (2006.01) A61K 31/517 (2006.01) A61K 31/519 (2006.01) A61K 31/5377 (2006.01) A61P 7/02 (2006.01) A61P 9/10 (2006.01) A61P 29/00 (2006.01) C07D 209/42 (2006.01) C07D 417/12 (2006.01) C07D

Patent

CA 2451605

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group (see above formula) in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N- oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

L'invention concerne des composés, des sels, des solvates ou des N-oxydes de ces composés, représentés par la formule générale suivante (1): Q?1¿-Q?2¿-T?0¿-N(R?1¿)-Q?3¿-N(R?2¿)-T?1¿-Q?4¿, dans laquelle R?1¿ et R?2¿ représentent chacun hydrogène, etc.; Q?1¿ représente hydrocarbyle à 5 ou 6 éléments, saturé ou insaturé, etc.; Q?2¿ représente une liaison unique, etc.; Q?3¿ représente le groupe suivant; (dans lequel Q?5¿ représente alkylène C¿1-8?, etc.); et T?0¿ et T?1¿ représentent chacun carbonyle, etc. Les composés selon l'invention sont utiles en tant que médicaments prophylactiques et/ou thérapeutiques contre l'infarctus cérébral, l'embolie cérébrale, l'infarctus du myocarde, l'angine, l'infarctus pulmonaire, l'embolie pulmonaire, la maladie de Buerger, la thrombose veineuse profonde, la coagulation intravasculaire disséminée, la thrombose provoquée par le remplacement d'une valve/jointure, la thrombose et la réocclusion provoquées par la reconstruction de la circulation, le syndrome de réponse inflammatoire systémique (SIRS), la dysfonction d'organes multiples (MODS), la thrombose pendant la circulation extracorporelle ou la coagulation sanguine lors d'un prélèvement sanguin.

Affiliated with

Also associated with

Rating

Diamine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diamine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diamine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1714747